
Clarity Pharmaceuticals’ Bold Leap: The New Frontier in Cancer Treatment Captivates Investors
Clarity Pharmaceuticals Ltd’s (ASX: CU6) shares surged by 12% following a groundbreaking announcement in cancer therapy innovation. The company focuses on a fibroblast activation protein (FAP)-targeted radiopharmaceutical, revolutionizing cancer treatment by targeting tumor stroma rather than cancerous cells directly. Key innovation centers